Savara (SVRA) has received a new Buy rating, initiated by LifeSci Capital analyst, Francois Brisebois.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Francois Brisebois has given his Buy rating due to a combination of factors including the promising potential of Savara’s key product, MOLBREEVI, which is aimed at treating autoimmune pulmonary alveolar proteinosis (aPAP). This rare and chronic disease currently lacks approved treatments in the US and EU, with whole lung lavage being the only available option. The positive Phase 3 results published in the New England Journal of Medicine, showing significant improvements in patients, highlight MOLBREEVI’s potential to address the underlying pathophysiology of aPAP.
Furthermore, expert feedback suggests that MOLBREEVI could achieve blockbuster status in the US market, with minimal competition from biosimilars due to its unique formulation as a large inhaled biologic. The anticipated resubmission of the Biologics License Application (BLA) by the end of 2025 and potential approval by mid-2026, along with the alignment with the FDA on manufacturing, further de-risk the investment. The robust safety and efficacy profile, as evidenced by the durability of effect and favorable safety data, reinforce the confidence in MOLBREEVI’s market potential.